BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Axis Capital upgrades Alembic Pharma to hold
Axis Capital has upgraded Alembic Pharma to 'hold' from 'sell' for target of Rs 600/share. It says company is fast-tracking R&D initiatives and capacity expansion remains the key focus. It adds that the US revenues have benefited from gAbilify in FY16 and company is building infrastructure by investing extensively. Oncology, injectables & dermatology will drive growth for the company going ahead.